VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
SPRY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HomeStocksSPRYInstitutional Holders

SPRY logoARS Pharmaceuticals, Inc. (SPRY) Institutional Ownership

Q2 2026 13F Data|Updated 2026-11-18

✨

Institutional ownership decreased this quarter (-2.93 pp), while top 10 holders maintain a highly concentrated 67.4% of value.

Institutional Ownership
Can exceed 100% due to securities lending, short interest, and reporting timing differences.
91.4%$709M total value · ▼ 2.93 pp vs prior quarter
Smart Money Score
Based on ownership concentration, fund quality, buying/selling activity, ownership indicators, and institutional trend.
52 / 100Neutral
Institutions & Flow206 holders+3 net flow (+34 / -31)

AI Insights & Key Takeaways

  • Positive Institutional Flow (+3)
  • Marquee funds including Millennium Management Llc and Third Point Llc maintain significant positions
  • Top 10 holders control 67.4% of institutional value
  • No Insider Signal

Top Institutional Holders of SPRY

Ranked by reported Q2 2026 13F market value

Top 10 Holders
67.4%
Top 25 Holders
86.8%

Share of total reported institutional value in SPRY held by the largest 10 / 25 filers.

#InstitutionShares HeldMarket ValueQoQ ChangeOwnership %% of Fund
1RA CAPITAL MANAGEMENT, L.P.10.9M$87.0M0.0%10.937%0.76%
2Rubric Capital Management LP8.5M$68.4M+6.8%8.601%0.63%
3ORBIMED ADVISORS LLC8.3M$66.4M0.0%8.347%1.23%

Quarterly Institutional Activity

Filings activity in SPRY during Q2 2026, grouped by how each filer changed its position.

OverviewNew Buyers34Added To70Trimmed91Exited31
  • RA CAPITAL MANAGEMENT, L.P.$87.0M
  • ORBIMED ADVISORS LLC$66.4M

SPRY Institutional Ownership by Quarter

8 quarters of 13F filings · Δ columns show change vs prior quarter

QuarterInst. HoldersΔ HoldersOwnership %Δ OwnershipTotal 13F ValueΔ Value
Q2 2026206+1.5%91.44%2.93 pp$709M3.6%
Q1 2026203+6.8%94.37%+4.12 pp$735M28%
Q4 2025190+0.5%90.25%+3.60 pp$1.02B+21%
Q3 2025189+1.1%86.65%+0.64 pp$844M42%
Q2 2025187+2.2%86.01%+9.50 pp$1.45B+57%
Q1 2025183+13%

How SPRY Compares to Peers

Institutional ownership and quarterly buying activity across the largest Immunology Biotech peers.

TickerCompanyMarket CapInst. OwnershipHoldersNet Buyers − Sellers
LKFTLakefront Biotherapeutics N.V.$2.19B49.6%79-12
YARWYarrow Bioscience Inc$145M1.2%47+2
RKTORocket One Inc.$9M7.9%22+3

SPRY — Frequently Asked Questions

Quick answers to the most common questions about buying SPRY stock.

What percentage of SPRY is owned by institutions?

Based on Q2 2026 13F filings, institutional ownership of ARS Pharmaceuticals, Inc. stands at 91.4%, held across 206 reporting institutions.

Who is the largest institutional holder of SPRY?

RA CAPITAL MANAGEMENT, L.P. is the largest reported institutional holder of SPRY, with approximately 10,860,977 shares worth $0.09B as of Q2 2026.

Is SPRY a hedge fund favorite?

Yes — 3 widely-followed marquee investors appear among the top 25 institutional holders of SPRY, including MILLENNIUM MANAGEMENT LLC, Third Point LLC, CITADEL ADVISORS LLC.

What is SPRY's Smart Money Score?

Our composite Smart Money Score for SPRY is 52 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.

How many institutions bought SPRY this quarter?
4DEERFIELD MANAGEMENT COMPANY, L.P.7.5M$60.1M0.0%7.556%0.63%
5BlackRock, Inc.5.3M$42.5M+6.0%5.349%0.00%
6Tyro Capital Management LLC4.5M$35.7M+50.2%4.491%8.01%
7Aberdeen Group plc4.2M$33.4M+1.4%4.200%0.05%
8SR ONE CAPITAL MANAGEMENT, LP4.0M$32.1M0.0%4.041%3.09%
9STATE STREET CORP3.7M$29.9M+2.4%3.757%0.00%
10Capital World Investors2.8M$22.1M—2.774%0.00%
11VANGUARD CAPITAL MANAGEMENT LLC2.6M$20.5M+0.4%2.571%0.00%
12MILLENNIUM MANAGEMENT LLC2.5M$20.2M-57.9%2.539%0.01%
13UBS Group AG1.9M$15.5M-14.2%1.953%0.00%
14GEODE CAPITAL MANAGEMENT, LLC1.7M$13.6M+11.3%1.711%0.00%
15BOOTHBAY FUND MANAGEMENT, LLC1.6M$12.8M+539.1%1.613%0.17%
16GENERAL AMERICAN INVESTORS CO INC1.1M$9.1M+55.8%1.141%0.54%
17Third Point LLC1.0M$8.0M0.0%1.007%0.17%
18PEREGRINE CAPITAL MANAGEMENT LLC672K$5.4M—0.677%0.17%
19Tejara Capital Ltd607K$4.9M+188.5%0.611%2.00%
20ADAR1 Capital Management, LLC601K$4.8M-55.9%0.605%0.22%
21Pavaki Capital Management LLC580K$4.6M—0.584%0.70%
22VANGUARD PORTFOLIO MANAGEMENT LLC567K$4.5M+11.0%0.571%0.00%
23CITADEL ADVISORS LLC567K$4.5M-69.2%0.571%0.00%
24CHARLES SCHWAB INVESTMENT MANAGEMENT INC551K$4.4M+3.4%0.555%0.00%
25NORTHERN TRUST CORP549K$4.4M+3.7%0.553%0.00%

denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in SPRY — a direct measure of their conviction.

DEERFIELD MANAGEMENT COMPANY, L.P.
$60.1M
  • SR ONE CAPITAL MANAGEMENT, LP$32.1M
  • MILLENNIUM MANAGEMENT LLC$20.2M
  • UBS Group AG$15.5M
  • Third Point LLC$8.0M
  • ADAR1 Capital Management, LLC$4.8M
  • CITADEL ADVISORS LLC$4.5M
  • LEVIN CAPITAL STRATEGIES, L.P.$4.4M
  • Empire Life Investments Inc.$3.8M
  • UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME$3.7M
  • 76.51%
    +4.26 pp
    $927M
    +25%
    Q4 2024162+10%72.25%+5.84 pp$741M19%
    Q3 2024147—66.41%—$912M—

    Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.

    34 institutions opened new positions in SPRY during Q2 2026, while 31 fully exited. 70 added to existing positions and 91 trimmed.

    How is institutional ownership of SPRY changing?

    SPRY institutional ownership fell by 2.93 percentage points quarter-over-quarter, with a net change of +3 holders.

    How concentrated is SPRY ownership among the top holders?

    The top 10 institutions account for 67.4% of all reported 13F value in SPRY, and the top 25 account for 86.8%.

    How does SPRY compare to Immunology Biotech on institutional ownership?

    Across the largest Immunology Biotech peers, institutional ownership levels are: LKFT (49.6%), YARW (1.2%), RKTO (7.9%). See the peer comparison table on this page for net buyer activity by company.

    Where does this SPRY institutional ownership data come from?

    All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.

    SPRYARS Pharmaceuticals, Inc.
    $3.69$366M
    Overview & Tools
    OverviewChart Terminal ↗Visualize
    Valuation & Forecasts
    Valuation ModelsEstimatesDCF Model
    Price & Analyst Data
    Analyst TargetsPrice History
    Financial Statements
    Income StatementBalance SheetCash FlowRatios & Margins
    Performance
    P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
    Discovery & Screens
    Live BreakoutsStock ScreenerOwnership